About: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 14 July 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в липні 2009 (uk) مقالة علمية نشرت في 14 يوليو 2009 (ar) scientific article published on 14 July 2009 (en)
publication date	wds:Q37330719-2FB585EC-4C5F-4ADB-B5D8-39DD246E388E
publication date	2009-07-14 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37330719-1622CDDB-7AEA-4A8A-8D73-A27E246E0705
language of work or name	English
exact match	wds:Q37330719-8CD3BF23-8CB1-4CF9-AAC2-D2CF768EE276
exact match	https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605177
cites work	wds:Q37330719-036A2CA4-8433-40F0-80F4-E6DE48625AA9 wds:Q37330719-0435D829-74AB-4068-A3B0-691984F9336B wds:Q37330719-26860FE5-0495-4FFF-B52D-E2E7FED267A3 wds:Q37330719-2CB023ED-FFE7-416B-BE59-08EAECCECD6A wds:Q37330719-38BFCB03-D60E-4FE8-B82F-32B27B227B12 wds:Q37330719-41D74C86-2EE1-46D8-930A-2E6A7E5DAFCA wds:Q37330719-47EEADEB-C4F7-453C-A063-3F7E676D1A0D wds:Q37330719-4B1535E2-BE01-48C3-8956-E4558F82DA10 wds:Q37330719-4EB7C457-7C64-465F-831C-25742F8F9D93 wds:Q37330719-5115B735-C3FF-4127-8F7F-24B96E8738AA wds:Q37330719-65541DA2-A581-4331-B033-9B4C192BE75E wds:Q37330719-758F5216-0B23-4756-A281-491D41D51030 wds:Q37330719-94DAAF2F-6A91-4D6E-8A33-E0373CEE59C3 wds:Q37330719-9E4DB30D-8561-422D-89F3-2A58C2C6B1AF wds:Q37330719-A0E7DE34-188A-44D0-AE4E-14F21DB8D06D wds:Q37330719-A32FA10A-66D0-4542-A803-62BEEF519133 wds:Q37330719-B8F692BA-5EA9-4233-AF83-3990FF0DF38D wds:Q37330719-BB0FCFFB-6C20-4126-8021-C6171B5C83D2 wds:Q37330719-BF5E0E98-623A-470A-ADBE-BBE6F3247F61 wds:Q37330719-DF723295-0378-4804-B050-769D931C780F wds:Q37330719-E7E397FC-1523-4F1A-811D-648F016B6E6D wds:Q37330719-E8708FB0-E60E-43CA-9CBF-EB675FE78712 wds:Q37330719-EEAB90AA-7322-4069-8A52-54565DF140A4 wds:Q37330719-FA2CF438-26F8-4DE0-8A4E-318E1A90305B
cites work	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Cetuximab for the treatment of colorectal cancer. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Recurrent KRAS codon 146 mutations in human colorectal cancer A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer K-ras mutations and benefit from cetuximab in advanced colorectal cancer. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Transformation Efficiency of RasQ61 Mutants Linked to Structural Features of the Switch Regions in the Presence of Raf New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada ras oncogenes in human cancer: a review Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.
author name string	wds:Q37330719-2CCE0E7B-7222-463D-B30D-93A3102F615A wds:Q37330719-3E8865C7-884F-44D1-83A7-1BD1B132D8EA wds:Q37330719-44471C95-5E2C-438E-A994-B30485B5EBE7 wds:Q37330719-8CD3B461-2511-4017-9C1A-7A62F39C901D wds:Q37330719-A84654CB-D3C6-472D-A4B1-8D5A4C3B3BF5 wds:Q37330719-B21AD0B6-8E4E-4539-8779-EE306A261FAC wds:Q37330719-B6CE1703-0DF3-46AB-A12B-E7D763A61752 wds:Q37330719-CB03E63F-B016-4184-96BF-FD528C02CF81 wds:Q37330719-F013198B-3CD2-49F4-A308-E1B28F1A8ACD
author name string	K Bencardino F Graziano G Masi V Catalano I Floriani M Magnani E Canestrari N Galluccio I Stasi
rdfs:label	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (en) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (nl) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (ast)
skos:prefLabel	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (en) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (nl) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (ast)
name	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (en) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (nl) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. (ast)
author	wds:Q37330719-01A4198C-6782-4E1F-B302-ACED228E2B91 wds:Q37330719-25184360-E1F1-40AB-B3FB-19EEE2E9B0B6

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software